GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexeo Therapeutics Inc (NAS:LXEO) » Definitions » Tax Rate %

Lexeo Therapeutics (Lexeo Therapeutics) Tax Rate % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Lexeo Therapeutics Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Lexeo Therapeutics's Tax Expense for the three months ended in Mar. 2024 was $0.00 Mil. Lexeo Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-21.68 Mil. Therefore, Lexeo Therapeutics's Tax Rate % for the quarter that ended in Mar. 2024 was 0.00%.

Lexeo Therapeutics Tax Rate % Historical Data

The historical data trend for Lexeo Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexeo Therapeutics Tax Rate % Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tax Rate %
- - - -

Lexeo Therapeutics Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexeo Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Lexeo Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2023 )/Pre-Tax Income (A: Dec. 2023 )
=0/-66.394
=0.00 %

Lexeo Therapeutics's Tax Rate % for the quarter that ended in Mar. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2024 )/Pre-Tax Income (Q: Mar. 2024 )
=0/-21.682
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexeo Therapeutics Tax Rate % Related Terms

Thank you for viewing the detailed overview of Lexeo Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexeo Therapeutics (Lexeo Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexeo Therapeutics Inc (NAS:LXEO) » Definitions » Tax Rate %
Comparable Companies
Traded in Other Exchanges
N/A
Address
345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Website
https://www.lexeotx.com
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Executives
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp, L.p. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Richard Nolan Townsend director, officer: Chief Executive Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Jenny Robertson officer: Chief Legal and Admin. Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Paul Mccormac officer: Chief Technical Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Bernard Davitian director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Eric Adler officer: Chief Scientific Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Brenda Cooperstone director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Longitude Venture Partners Iv, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Paula H Cholmondeley director 221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991
Reinaldo M Diaz director C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022
Mette Kirstine Agger director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830

Lexeo Therapeutics (Lexeo Therapeutics) Headlines

From GuruFocus

Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs

By GuruFocus Research • 12-13-2023